Patents by Inventor Paul B. Yu
Paul B. Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951156Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-? ligand trap, and methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-? signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-? ligand trap to reduce right ventricular systolic pressure in a subject.Type: GrantFiled: April 17, 2020Date of Patent: April 9, 2024Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA, INC.Inventors: Paul B. Yu, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves, Ravindra Kumar
-
Publication number: 20240083991Abstract: Antibodies, and antigen-binding fragments thereof, that specifically bind to bone morphogenetic protein-9 (BMP9) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.Type: ApplicationFiled: May 31, 2023Publication date: March 14, 2024Applicants: Pfizer Inc., The Brigham and Women's Hospital, Inc., The General Hospital CorporationInventors: Paul B. Yu, James Reasoner Apgar, Susan Adam Benard, Stephen Peter Berasi, Christine Huard, Oleg Victorovich Kovalenko, Lidia Mosyak, Xianchun Tang, Kathleen Elisabeth Tumelty, Luca Troncone, Ying Zhong
-
Publication number: 20230220085Abstract: Compositions and methods for selective targeting of BMP/TGF? signaling using heteromeric complexes, preferably comprising single chain variable domain (scFv) antibodies (Abs) targeting the extracellular domains of BMP type I and type II receptors.Type: ApplicationFiled: March 1, 2021Publication date: July 13, 2023Inventors: Paul B. Yu, Luca Troncone, Stephanie Kim
-
Patent number: 11654147Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).Type: GrantFiled: June 7, 2021Date of Patent: May 23, 2023Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Dept. of Health and Human ServicesInventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
-
Publication number: 20230000869Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).Type: ApplicationFiled: June 7, 2021Publication date: January 5, 2023Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
-
Publication number: 20210322548Abstract: The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGF?1, TGF?3, and/or GDF-15.Type: ApplicationFiled: April 26, 2021Publication date: October 21, 2021Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Lai-Ming YUNG, Paul B. YU
-
Patent number: 11027014Abstract: The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGF?1, TGF?3, and/or GDF-15.Type: GrantFiled: January 29, 2019Date of Patent: June 8, 2021Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Lai-Ming Yung, Paul B. Yu
-
Patent number: 11026947Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).Type: GrantFiled: April 26, 2018Date of Patent: June 8, 2021Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Dept, of Health and Human ServicesInventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
-
Publication number: 20200323955Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-? ligand trap, and methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-? signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-? ligand trap to reduce right ventricular systolic pressure in a subject.Type: ApplicationFiled: April 17, 2020Publication date: October 15, 2020Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA INC.Inventors: Paul B. YU, Asya GRINBERG, Dianne S. SAKO, Roselyne CASTONGUAY, Rita STEEVES, Ravindra KUMAR
-
Publication number: 20200179389Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).Type: ApplicationFiled: April 26, 2018Publication date: June 11, 2020Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
-
Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
Patent number: 10583143Abstract: Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.Type: GrantFiled: April 10, 2019Date of Patent: March 10, 2020Assignee: The Brigham and Women's Hospital, Inc.Inventors: Paul B. Yu, Jana Bagarova -
Patent number: 10513521Abstract: The present invention provides bicyclic heteroaryl inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. Exemplary compounds include those of Formula I: These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.Type: GrantFiled: July 14, 2015Date of Patent: December 24, 2019Assignees: The Brigham and Women's Hospital, Inc., University of Houston System, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Arthur Lee, John C. McKew, Paresma R. Patel, Paul B. Yu, Agustin H. Mohedas, Philip E. Sanderson, Gregory D. Cuny, Wei Zheng, Xiuli Huang
-
Publication number: 20190365857Abstract: The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGF?1, TGF?3, and/or GDF-15.Type: ApplicationFiled: January 29, 2019Publication date: December 5, 2019Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Lai-Ming Yung, Paul B. Yu
-
Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
Patent number: 10369152Abstract: Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.Type: GrantFiled: February 12, 2016Date of Patent: August 6, 2019Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Paul B. Yu, Jana Bagarova, Devaveena Dey -
METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF ABNORMAL BONE FORMATION IN A SOFT TISSUE
Publication number: 20190231779Abstract: Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.Type: ApplicationFiled: April 10, 2019Publication date: August 1, 2019Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Paul B. Yu, Jana Bagarova, Devaveena Dey -
Publication number: 20180333508Abstract: A method of detecting a disease associated with pulmonary vascular remodeling. The method includes administering a radioisotope-conjugated antibody against vascular endothelial growth factor (VEGF). The method further includes imaging said antibody using positron emission tomography (PET), computed tomography (CT), or magnetic resonance imaging (MIR). Retention of said antibody reflects vascular remodeling.Type: ApplicationFiled: November 3, 2016Publication date: November 22, 2018Inventors: Paul B Yu, Marcelo Dicarli
-
Patent number: 10017516Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.Type: GrantFiled: May 18, 2017Date of Patent: July 10, 2018Assignees: The Brigham and Women's Hospital, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of HealthInventors: Asaf Alimardanov, Gregory D. Cuny, Gurmit S. Grewal, Arthur Lee, John C. McKew, Agustin H. Mohedas, Min Shen, Xin Xu, Paul B. Yu
-
METHODS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF ABNORMAL BONE FORMATION IN A SOFT TISSUE
Publication number: 20180021340Abstract: Provided herein are methods and compositions for the treatment and/or prevention of abnormal bone formation in a soft tissue. In certain embodiments, the methods and compositions treat and/or prevent a disease or disorder comprising abnormal bone formation in soft tissue. Exemplary diseases or disorders that can be treated with the methods and compositions described herein include, but are not limited to, heterotopic ossification diseases such as fibrodysplasia ossificans progressive, anklyosing spondylosis, traumatic heterotopic ossification, burn- or blast-injury associated heterotopic ossification, and joint replacement surgery associated heterotopic ossification.Type: ApplicationFiled: February 12, 2016Publication date: January 25, 2018Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Paul B. Yu, Jana Bagarova, Devaveena Dey -
Publication number: 20170334918Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.Type: ApplicationFiled: May 18, 2017Publication date: November 23, 2017Inventors: ASAF ALIMARDANOV, GREGORY D. CUNY, GURMIT SINGH GREWAL, ARTHUR LEE, JOHN C. MCKEW, AGUSTIN H. MOHEDAS, MIN SHEN, XIN XU, PAUL B. YU
-
Publication number: 20170305883Abstract: The present invention provides small molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.Type: ApplicationFiled: October 1, 2015Publication date: October 26, 2017Inventors: Paul B. Yu, Gregory D. Cuny, Agustin H. Mohedas, Arthur Lee